Recently, the results of a Phase 2 trial evaluating the anti-PD-1 antibody MEDI0680 combined with anti-PD-L1 treatment durvalumab in patients with advanced or metastatic clear-cell renal cell carcinoma have been reported [27]. The gene discussed is PDCD1; the disease is clear cell renal carcinoma.